Table 3. Number of cases (N) and percentages of observed and expected genotypes of ESR1 PvuII, CYP2C19 and UGT2B15 in tamoxifen-treated patients.

	N observed	% observed	N expected	% expected	P
ESR1 PvuII
wt/wt	22	32	20.4	29.5	0.43
wt/vt	31	45	34.2	49.6
vt/vt	16	23	14.4	20.8
Total	69	100	69	100
CYP2C19
wt/wt	57	83	55.7	80.7	0.09
wt/*2	10	14	12.6	18.2
*2/*2	2	3	0.7	1
Total	69	100	69	100
UGT2B15
wt/wt	20	29	19.8	28.8	0.94
wt/*2	34	49	34.4	49.7
*2/*2	15	22	14.8	21.5
Total	69	100	69	100